Advertisement

Advertisement
Survivorship

Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer

With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD, Division Director, Reproductive Endocrinology and Infertility, University Hospitals of Cleveland, Case Western Reserve University. For girls, these consequences can include damage to the ovaries and infertility. Ovarian tissue cryopreservation prior to cancer treatment and then later reimplantation may be the best way to preserve fertility.

Leukemia

ADMIRAL Trial: More Than Standard Chemotherapy Needed for FLT3-Mutant Advanced AML

The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, shows the efficacy of a specific FLT3 inhibitor in patients with advanced acute myeloid leukemia (AML) and enhances the era of personalized medicine in leukemia.

Issues in Oncology
Breast Cancer
Survivorship
Prostate Cancer

Elevations in Cancer Incidence Among Responders to the WTC Site After the September 11 Attacks

We’ll start off this week on The ASCO Post Podcast by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes...

 

 

 


Advertisement
Pancreatic Cancer

Olaparib as Maintenance Therapy for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma

On December 27, 2019, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma, as detected by a U.S. Food and Drug Administration (FDA)-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. The FDA also approved the BRACAnalysis CDx test as a companion diagnostic for the selection of patients with pancreatic cancer for treatment with olaparib based upon the identification of deleterious or suspected deleterious germline mutations in BRCA1 or BRCA2.

Breast Cancer

Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer

A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with triple-negative breast cancer. However, the addition of the RANK ligand inhibitor denosumab to neoadjuvant chemotherapy had no impact on pathologic complete response. These preliminary findings of the pathologic complete response rates in the GeparX study were presented at the 2019 San Antonio Breast Cancer Symposium.

Advertisement




More Top Stories

Breast Cancer
Immunotherapy

Ralph R. Weichselbaum, MD, on Oligometastatic Cancer: The Role of Radioimmunotherapy

Breast Cancer

Does Adding Trastuzumab to Adjuvant Chemotherapy Improve Invasive Disease–Free Survival for Patients With HER2-Negative Breast Cancer?

As reported in the Journal of Clinical Oncology by Louis Fehrenbacher, MD, and colleagues, the phase III NSABP B-47/NRG Oncology trial has shown no invasive disease–free survival benefit with the addition of trastuzumab to adjuvant chemotherapy therapy in patients with HER2-negative breast cancer...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Icro Meattini, MD, on Breast Irradiation After Breast-Conservation Surgery: 10-Year Follow-up Results

Solid Tumors

Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma

In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma. The study included data on 51 patients from 18...

Breast Cancer

Does Adding Trastuzumab to Adjuvant Chemotherapy Improve Invasive Disease–Free Survival for Patients With HER2-Negative Breast Cancer?

As reported in the Journal of Clinical Oncology by Louis Fehrenbacher, MD, and colleagues, the phase III NSABP B-47/NRG Oncology trial has shown no invasive disease–free survival benefit with the addition of trastuzumab to adjuvant chemotherapy therapy in patients with HER2-negative breast cancer...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine

Gynecologic Cancers

Many Pelvic Examinations and Papanicolaou Tests Performed on Young Women May Be Unnecessary

Pelvic examinations and cervical cancer screenings are no longer recommended for most females under age 21 during routine health visits, but a new study has found that millions of young women are undergoing the tests, which can lead to false-positive testing, overtreatment, anxiety, and needless...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...